Biotechnology company Vaxxinity, whose focus is developing vaccines to treat chronic diseases, announced the results of Part B of a Phase 1 study of its experimental vaccine for Parkinson’s disease, UB-312. UB-312 contains a synthetic piece of alpha-synuclein, a protein implicated in neurodegeneration in diseases like Parkinson’s and other synucleinopathies, and stimulates the body to produce antibodies against it.
November 16, 2023 – Scottsdale, Ariz. – CND Life Sciences, a medical technology company pioneering the development of skin-based tests to help clinicians diagnose neurodegenerative diseases and other neurologic disorders, has been named a 2023 Fast Lane Honoree by the Arizona Bioindustry Association (AZBio). The award is given to a select few companies each year for achieving outstanding milestones in the previous 18 months.
Lipids are thought to play an important role in the aggregation of alpha-synuclein and are found in Lewy bodies, the hallmark of Parkinson’s disease. Research to date on the molecular interaction between lipids and alpha-synuclein—utilizing experimental methods such as nuclear magnetic resonance, electron paramagnetic resonance, and neutron reflectivity—has mostly been carried out at relatively low concentrations of alpha-synuclein.
A recently published study in Neurology showed that higher levels of physical activity were associated with a lower incidence of Parkinson’s Disease (PD) in a large cohort of women.
A recently published study in Neurology showed that higher levels of physical activity were associated with a lower incidence of Parkinson’s Disease (PD) in a large cohort of women.
A recently published study in Neurology showed that higher levels of physical activity were associated with a lower incidence of Parkinson’s Disease (PD) in a large cohort of women.
Vaxxinity, Inc. announced that its investigational synthetic peptide vaccine for Parkinson’s, UB-312, met the primary endpoints of a Phase 1 clinical trial designed to assess its tolerability and efficacy in creating an antibody response against toxic aggregates of alpha-synuclein.
Enterin Inc., a biopharmaceutical company based in Philadelphia, is aiming to become the first to develop a treatment that targets the gut-brain axis in patients with neurodegenerative disease.
CND Life Sciences, a medical technology company pioneering the development of skin-based tests to help clinicians diagnose neurodegenerative diseases and other neurologic disorders, has been awarded accreditation by the College of American Pathologists (CAP). Recognized for rigorous and robust standards, CAP accreditation elevates quality in important ways so that laboratories can contribute to improved patient outcomes.
Topline results from the Synuclein-One Study, presented at the American Academy of Neurology Annual Meeting in Boston April 22-27, were covered by several news outlets over the past two weeks.